📅 PUBMED DAILY TRIAGE — 2026-04-16

Window: 2026-04-15T09:00:00Z → 2026-04-16T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~80+ candidates | Articles evaluated (scored): 15 High priority: 3 | Standard: 9 | Low/archive: 3 | Unsolicited finds: 0 Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Novel Therapeutics: Immunotherapy / CAR-T

TR-2026-04-16-001 · Demethylation-primed tandem CD19/CD20 CAR T cells in r/r B-cell lymphoma: phase I/II trial · 9/10 · Wang C et al., Nature Communications

87% complete response rate and 77% 2-year PFS in 23 r/r NHL patients — decitabine epigenetic priming of dual-target CAR-T establishes a novel, clinically validated paradigm for durable cellular immunotherapy.

Early Cancer Detection (Liquid Biopsy / ctDNA)

TR-2026-04-16-002 · Integrative fragmentomic and mutational signature profile of plasma cfDNA for early lung cancer detection · 8/10 · He J et al., NPJ Precision Oncology

Multi-omics cfDNA assay (n=1,600 training + external validation) achieves AUC 95.7% and 85.9% sensitivity; outperforms LDCT in simulated population screening — strengthens liquid biopsy case for broad lung cancer screening.

Cardiovascular-Metabolic: Cardiometabolic Risk

TR-2026-04-16-003 · Association between overuse of short-acting β2-agonists and MACE risk in asthma · 8/10 · Lai CC et al., Thorax

In 231,970 asthma patients, SABA overuse (≥3 canisters/year) associated with aHR 1.25 for MACE, 1.40 for mortality, with dose-response peaking at 6-8 canisters/year — directly actionable finding for asthma management and CV risk monitoring.

🟢⚪ STANDARD (5-7) — Top by Topic

Hematologic Malignancies

• TR-2026-04-16-004 · Disparities in blood cancer survival in UK 2009-2019 (n=413,286) · 7/10 · Hoang J et al., BJC Reports | Public Health / UNDERSERVED_POPULATION
• TR-2026-04-16-007 · PROTAC MDM2 degrader MD-265 in primary AML cells + PDX (IC50=16nM, 150× vs MDM2i) · 6/10 · Kandarpa M et al., Leukemia | Drug Development / PROMISING_PRELIMINARY
• Additional: PMID 41986622 — MCL evolving therapeutics review (Leukemia) — 4/10 [not kept as full record; borderline LOW]

Early Cancer Detection / Liquid Biopsy

• TR-2026-04-16-006 · Tucidinostat + metronomic capecitabine + ET, Phase 2, r/r HR+/HER2- ABC (n=66, ORR 25.8%) · 7/10 · Wu HL et al., Signal Transduction Targeted Ther | Treatment Innovation + ctDNA biomarker
• TR-2026-04-16-008 · cfDNA methylation marker outperforms PD-L1 CPS for gastric cancer immunotherapy response (n=94) · 6/10 · Fang J et al., J Immunother Cancer | Diagnostics / PROMISING_PRELIMINARY

Precision Oncology / Genomic Medicine

• Additional STANDARD: PMID 41986521 — KRAS G12C NSCLC clinicopathologic features n=279 (Virchows Arch) — 5/10; PMID 41986599 — SLIDE-EX deep learning for cell-type gene expression from histopathology (NPJ Precis Oncol, NCI) — 6/10

Novel Therapeutics (Immunotherapy / Mechanistic)

• TR-2026-04-16-012 · mRNA vaccines engage unconventional CD8+ T cell priming via cross-dressing (Nature) · 5/10 · Jo S et al. | Mechanistic preclinical; foundational for cancer vaccine optimization [score capped for non-human]

Cardiovascular-Metabolic / GLP-1-Adjacent

• TR-2026-04-16-010 · Rare sugars allulose + tagatose meta-analysis: reduce postprandial glucose/insulin (20 trials, n=1,033) · 6/10 · Osborn L et al., Am J Clin Nutr | Prevention / NEAR_TERM_IMPLEMENTABLE

Aging / Longevity / Population Health

• TR-2026-04-16-011 · Gene×environment glucose homeostasis trajectories in youth, ALSPAC n=8,783 · 6/10 · Gamache I et al., Diabetologia | Genomics / Prevention

Rare Diseases / Gene Therapy

• TR-2026-04-16-005 · STRIPE targeted long-read RNA-seq for rare disease diagnosis: 5 new diagnoses in n=88 · 7/10 · Wang R et al., Science Advances | Diagnostics / NEAR_TERM_IMPLEMENTABLE
• TR-2026-04-16-009 · Pediatric X-linked ALD HSCT outcomes + 3 novel ABCD1 variants (n=31) · 6/10 · Li J et al., Eur J Pediatr | Treatment / UNDERSERVED_POPULATION

💡 UNSOLICITED FINDS

None identified today. Sentinel scan (n=10 candidates) produced no high-signal finds outside watchlist topics; all notable sentinel hits were already captured by watchlist searches.

📊 TODAY'S BREAKDOWN

By research category:

• Treatment Innovation: 4 (TR-001, TR-007, TR-009, TR-012)
• Early Detection: 2 (TR-002, TR-014)
• Diagnostics: 3 (TR-005, TR-008, TR-015)
• Public Health / Prevention: 3 (TR-003, TR-004, TR-010)
• Genomics/Precision Medicine: 2 (TR-006, TR-011)
• Drug Development: 2 (TR-007, TR-013)
• Other / Low: 1 (TR-015)

By evidence maturity:

• Potentially Practice-Changing: 1 (TR-001 — DAC-primed CAR-T)
• Validated: 5 (TR-002, TR-003, TR-004, TR-005, TR-009, TR-010, TR-011)
• Exploratory: 6 (TR-006, TR-007, TR-008, TR-012, TR-013, TR-014, TR-015)

By watchlist topic (reviewed / kept / highest score):

By source type: peer_reviewed: 15 | preprint: 0

Topics with zero 8+ articles this run:

• CBC-based diagnostics and machine learning in hematology (10th consecutive sparse run)
• AI/ML in clinical diagnostics and imaging
• Precision oncology and genomic medicine
• Aging, longevity, and population health
• Rare diseases with high unmet need

🔧 RUN NOTES

• Window expansion: Not triggered (≥5 relevant articles found in 24-hour window)
• Truncation: Not triggered; all topics stayed within candidate cap
• CBC/ML hematology topic: 10th consecutive run with max score ≤3; no dedicated CBC+ML hematology articles entered PubMed in this window. Recommend watchlist review or query broadening if persistent.
• PMID 41986809: Retraction notice (Gene Therapy); excluded from scoring per default exclusion rules
• PMID 41986639 (oral SCC autoantibodies): Abstract not returned by efetch; scored as title-only (cap 3). Recommend manual check via PubMed.
• Rolling 7-day view on sparse topics: CBC/ML hematology has produced zero HIGH articles for 10 consecutive days; AI/ML diagnostics topics are dominated by non-hematology applications. GLP-1 cardiometabolic: producing 1 HIGH today (SABA overuse), breaking a dry streak.
• Notable pattern: DAC-primed CAR-T (PMID 41986386) is the standout find of the run — 87% CRR and 77% 2-year PFS in an explicitly powered Phase I/II trial is exceptional in r/r NHL context.